Skip to main content
Premium Trial:

Request an Annual Quote

Celera Finds Foothold in Japan

Premium

A little flattery never hurt, right? Perhaps that’s why Craig Venter, eager to expand Celera’s horizons, says Japan will play an increasingly significant role in what he calls the “golden age of discovery” in proteomics, disease prevention, and medical treatment.

“[Japan] could end up leading the world in terms of the implementation of new ideas in medicine,” Venter says. “We think some of the leading science in genomics is now beginning to take place in Japan. And Celera is very interested in helping to participate in that science.”

Celera demonstrated its commitment to the country by announcing a deal to acquire a minority interest in emerging Japanese firm HuBit Genomix, which focuses on the discovery and association of genes and SNPs for use in therapeutics and diagnostics. The size of the deal was not disclosed.

Japanese representatives at a life science symposium indicated their willingness to consider potential collaborations.

— Sara Harris

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.